SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

UNC's Gedas Bertasius uses basketball to train computers
Today, the same instincts that once helped Gedas Bertasius scan a basketball court — where the pass is headed, how the defense might collapse —...
Tue Mar 31, 2026

Carolina Across 100 launches final program
UNC-Chapel Hill’s Carolina Across 100 initiative welcomes 10 teams covering 19 counties to its final program Our State, Our Future. This culminating program marks the...
Tue Mar 31, 2026

Interview with comedian, UNC alum Lewis Black
Lewis Black, the now 77-year-old stand-up legend has retired from touring, and his recent “Goodbye Yeller Brick Road” performances were his last. But Black, the...
Mon Mar 30, 2026

Here are 5 things I love about Carolina
Rameses at Home - One of my favorite experiences in the community is when I drive past the Hogan family farm and I catch a...
Sat Mar 28, 2026